CooperCompanies (COO) Q3 2025 earnings review
Revenue Slowdown Masks Margin Strength; FY25 Guidance Cut on CVI Weakness
CooperCompanies missed Q3 revenue expectations as organic growth slowed sharply to 2% (from 7% last quarter), driven by a surprising deceleration in the core CooperVision (CVI) segment to just 2% organic growth. Management attributes this to a temporary disruption as customers shift from the `clarity` brand to the premium `MyDay` brand, alongside weakness in low-margin Asia-Pacific e-commerce. Despite the top-line miss, the company demonstrated strong operational control, expanding non-GAAP operating margins and delivering a 15% YoY increase in Non-GAAP EPS. Reflecting this split performance, Cooper cut its full-year organic revenue growth guidance to 4-4.5% (from 5-6%) but slightly raised its Non-GAAP EPS forecast.
🐂 Bull Case
The company is proving it can grow earnings even with slowing revenue, highlighting strong cost control and operational leverage. Raising the full-year EPS guidance despite cutting the revenue outlook is a clear sign of management's confidence in its profitability.
The revenue disruption is attributed to a positive long-term trend: customers trading up to the premium MyDay product. An aggressive rollout of fitting sets and trial lenses is underway and should convert to high-margin revenue in coming quarters.
🐻 Bear Case
The sudden drop in CooperVision's growth from 7% to 2% is alarming. Management's explanation of a temporary `clarity`/`MyDay` transition may be optimistic, and it could signal broader market softness or heightened competitive pressure.
The 5% organic decline in Asia-Pacific is a significant concern. While blamed on low-margin e-commerce, it follows a similar issue in Q1 and could be an indicator of wider regional challenges or market share loss.
⚖️ Verdict: ⚪
Mixed. The impressive EPS performance and margin control demonstrate strong management execution. However, the sharp slowdown in the core CVI business, which management expects to persist in Q4, is a major concern. The bull case relies heavily on the `MyDay` transition converting to revenue smoothly, which is not guaranteed. The guidance cut signals the current headwinds are significant.
Key Themes
CooperVision's Growth Hits a Wall
CooperVision's organic growth fell sharply to 2% in Q3 from 7% in Q2, driving the company's overall revenue miss. This was primarily caused by the Asia-Pacific region, which declined 5% organically. Management attributes the global slowdown to a 'cannibalization' effect as a major rollout of premium `MyDay` fitting sets caused customers to pause orders for the `clarity` lens brand. While this may be a positive long-term trade-up, the near-term impact is severe, and guidance for Q4 (2-4% organic) suggests a slow recovery.
MyDay Positioned as the Future Growth Engine
After being supply-constrained, Cooper is now aggressively rolling out its premium MyDay daily lens portfolio. Management noted a massive year-over-year increase in fitting activity and trial lenses being placed in the market. MyDay itself grew double-digits in Q3, and the company has won over 30 new private label contracts for the brand. This is the core of the bull thesis, with management expecting the current fitting activity to convert into accelerated, high-margin revenue growth in FY26.
Margin Expansion Demonstrates Strong Execution
Despite the revenue shortfall, Cooper delivered a 15% YoY increase in non-GAAP EPS to $1.10. Non-GAAP operating margin expanded to 26.1%, driven by manufacturing efficiency gains, favorable product mix, and disciplined SG&A leverage. The decision to raise the full-year EPS guidance while cutting the revenue forecast signals strong confidence in the company's ability to manage profitability through top-line volatility.
Contradiction: Revenue Growth is Being Sacrificed for the MyDay Transition
Management presents the shift to MyDay as a positive strategic move. However, the data shows this transition is currently destroying, not creating, top-line growth. The full-year CVI organic growth guidance was cut from a midpoint of 6.5% last quarter to 4.5% now. This indicates that the premium pricing of MyDay is not nearly enough to offset the volume declines from `clarity`, leading to a net negative impact on revenue that is expected to continue.
MiSight Continues Strong Growth Trajectory
The MiSight myopia management lens remains a key growth driver, with sales up 23% in Q3. The company is on track to achieve its $100 million sales target for the year. Key future catalysts include an upcoming launch in Japan and the planned 2026 rollout of `MyDayMySite` across Europe and select APAC countries, which will combine their premium lens with their leading myopia technology.
Fertility Segment Remains Soft
CooperSurgical's Fertility segment grew just 3% organically, following 2% growth in Q2. Management continues to cite market pressure, with clinics managing cash conservatively by delaying capital purchases, alongside ongoing cycle softness in the Asia-Pacific region. While the long-term outlook is positive, the segment has underperformed expectations for most of FY25.
Other KPIs
Management provided a strong multi-year outlook, expecting to generate approximately $2 billion in free cash flow over fiscal years 2026-2028. This signals a significant increase in cash generation as the heavy CapEx cycle for MyDay capacity expansion concludes, allowing for a greater focus on debt reduction and share repurchases.
The company continues to actively return capital to shareholders, repurchasing 724.3 thousand shares in the quarter. Approximately $164 million remains available under the current share repurchase authorization.
The company lowered its FY25 organic revenue growth guidance to a midpoint of 4.25% from 5.5% last quarter. Simultaneously, it raised its non-GAAP EPS guidance to a midpoint of $4.10 from $4.08 previously, reflecting confidence in offsetting the revenue weakness through operational efficiencies.
Guidance
Decelerating. The guidance implies that the weakness seen in Q3 (2% organic growth) will persist through the end of the fiscal year, with no sharp V-shaped recovery expected.
Decelerating. This represents a significant reduction from the 5-6% organic growth guided last quarter, driven entirely by the lowered outlook for the CooperVision segment.
Decelerating. This is the core of the guidance revision, cut from 6-7% last quarter. It reflects management's expectation that the `clarity`/`MyDay` transition and Asia-Pacific weakness will continue to be significant headwinds.
Stable. This range was slightly raised from $4.05 - $4.11. The midpoint of $4.10 implies approximately 11% YoY growth from FY24's $3.69, demonstrating that profitability is being protected from the top-line slowdown.